deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT00502034

Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.

Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC).

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica

Conditions Carcinoma, Renal Cell
Interventions Interferon Alfa-2a Interleukin-2
Updated 5 times since 2017 Last updated: Jul 9, 2013 Started: Jul 31, 1994 Primary completion: Apr 30, 2007 Completion: Jun 30, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00502034, this PHASE3 trial focuses on Carcinoma, Renal Cell and remains completed. Sponsored by Gruppo Oncologico Italiano di Ricerca Clinica, it has been updated 5 times since 1994, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jul 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gruppo Oncologico Italiano di Ricerca Clinica
Data source: Gruppo Oncologico Italiano di Ricerca Clinica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations